高凌信息(688175.SH):多名股東擬合計減持不超5.66%股份
格隆匯6月24日丨高凌信息(688175.SH)公佈,因股東資金需求,公司股東漢虎納蘭德、高靈投資、深圳科微、清科和清一號、中電科國元及嘉興戰新擬通過集中競價交易、大宗交易或兩種方式相結合的方式減持所持公司股份,減持股份數量合計不超過732.16萬股,佔公司總股本比例不超過5.66%。其中,單個股東及其一致行動人若通過集中競價交易方式減持股份的,連續90個自然日內,減持股份的總數不超過公司股份總數的1%,若通過大宗交易方式減持股份的,連續90個自然日內,減持股份的總數不超過公司股份總數的2%。
上述減持自減持計劃公告披露之日起3個交易日後的3個月內進行,減持價格按市場價格確定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.